HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION
PLYMOUTH MEETING, Pa., July 20, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with...